Focus on Quetiapine
- 1 January 1999
- journal article
- review article
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 15 (3), 145-151
- https://doi.org/10.1185/03007999909114085
Abstract
Quetiapine fumarate is a novel dibenzothiazepine antipsychotic developed by Zeneca. It is marketed under the trade name 'Seroquel'. Quetiapine is well tolerated and clinically effective in the treatment of schizophrenia. The initial hope of investigators was that quetiapine would have antipsychotic potential and that it might share some of the properties of clozapine without its toxicity to white blood cells. The effective dosage range is usually 300-450 mg/day split into two doses. The dose is titrated upwards from 25 mg twice daily from day 1 to 300 mg/day on day 4. Elderly patients or patients with liver problems should be started on lower doses. It is both superior to placebo and comparable to haloperidol in reducing positive symptoms at doses ranging from 150 mg/day to 750 mg/day, and is an effective treatment for negative symptoms. Somnolence is the most common adverse event. Abnormalities of the QT interval on ECG appear very infrequently and there is no need for a baseline ECG or blood pressure monitoring, as used to be the case with sertindole. There is no need for haematological monitoring as with clozapine. Quetiapine, across the full dosage range, is associated with no greater extrapyramidal symptoms than placebo. Quetiapine's general efficacy and side-effect profile suggest that, unless there are unforeseen post-marketing complications, it deserves a major place in the initial and long-term management of schizophreniform disorders.Keywords
This publication has 13 references indexed in Scilit:
- Psychopharmacology: Antipsychotic Medications and FertilityPsychiatric Services, 1998
- Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.Psychopharmacology, 1998
- QuetiapineCNS Drugs, 1998
- A comparison of quetiapine and chlorpromazine in the treatment of schizophreniaActa Psychiatrica Scandinavica, 1997
- Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placeboBiological Psychiatry, 1997
- Quetiapine in Patients With SchizophreniaArchives of General Psychiatry, 1997
- ICI 204, 636: A New Atypical Antipsychotic DrugThe British Journal of Psychiatry, 1996
- ICI 204,636, an Atypical AntipsychoticJournal of Clinical Psychopharmacology, 1996
- ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophreniaClinical Therapeutics, 1995
- Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: Similarities to clozapinePsychopharmacology, 1994